TrialCancer chemotherapy and pharmacology2010

Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer.

Yago Nieto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.